Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32530468.
- Also identified by DOI 10.1001/jamanetworkopen.2020.5837 and PMC identifier 7292997.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cohort study investigates whether <i>MUC16</i> variation could be a useful biomarker for immune checkpoint inhibitor (ICI) therapy.
Medical subject headings
- Antineoplastic Agents, Immunological
- CA-125 Antigen
- Membrane Proteins
- Neoplasms